# ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

> **NCT03732664** · PHASE1 · COMPLETED · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 27 (actual)

## Conditions studied

- High-Risk Resectable NSCLC

## Interventions

- **DRUG:** Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab

## Key facts

- **NCT ID:** NCT03732664
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2023-03-23
- **Final completion:** 2023-03-23
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732664, "ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03732664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*